Article Text

Download PDFPDF
Palliative urinary diversion in patients with malignant ureteric obstruction due to gynaecological cancer
  1. Tamar Perri1,2,
  2. Elad Meller1,2,
  3. Gilad Ben-Baruch1,2,
  4. Yael Inbar2,3,
  5. Sara Apter2,3,
  6. Lee Heyman2,3,
  7. Zohar Dotan2,4 and
  8. Jacob Korach1,2
  1. 1Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel
  2. 2Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
  3. 3Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel
  4. 4Department of Urology, Sheba Medical Center, Tel Hashomer, Israel
  1. Correspondence to Dr Tamar Perri, Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer, Israel; tamarperri{at}gmail.com

Abstract

Objectives To identify factors aiding the selection of patients with gynaecological cancer with malignant urinary obstruction who are least likely to benefit from palliative urinary diversion (UD), and to create a risk-stratification model for decision-making.

Methods This historic cohort study comprised 74 consecutive patients with urinary obstruction resulting from gynaecological malignancies. All underwent palliative UD by percutaneous nephrostomy (PCN). Using the Cox proportional hazards regression model and Kaplan-Meier curves with the log-rank test, we developed a prognostic score identifying candidates least likely to benefit from the intervention.

Results The median follow-up was 4.72 (range 0–5.71) years. Hydronephrosis was diagnosed in most patients on recurrent or persistent disease (81%). It was bilateral in 37.8%. Intervention-related complications included urinary sepsis (8%), catheter dislodgment requiring replacement (17%) and gross haematuria necessitating blood transfusions (13%). After PCN, conversion to an internal ureteral stent was feasible in 46%. The median survival was 11.13 (range 0–67) months. Two patients died within a month of UD. Multivariate analysis identified diabetes mellitus (DM), poor Eastern Cooperative Oncology Group (ECOG) performance status >1 and ascites as significant negative survival factors. A prognostic index based on those factors identified the short-term and long-term survivors. Risk factor-based mortality HRs were 11.37 (95% CI 4.12 to 31.37) with one factor, 26.57 (95% CI 9.14 to 77.26) with two factors and 67.25 (95% CI 15.6 to 289.63) with three factors (all with p<0.0001).

Conclusions Our proposed prognostic index, based on ascites, ECOG performance status and DM, might help select patients with gynaecological cancer least likely to benefit from palliative UD.

  • genitourinary
  • clinical decisions
  • quality of life
View Full Text

Statistics from Altmetric.com

Footnotes

  • TP and EM contributed equally.

  • Contributors Work conception and design: TP, GB-B, ZD, JK. Data acquisition, analysis and interpretation: TP, EM, YI, SA, LH, GB-B, ZD, JK. Work draft: TP, EM. Critical revisions: TP, EM, LH, YI, SA, GB-B, JK, ZD. All authors approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Approval was given by the Sheba Medical Center Ethics Committee (project number 2699-15-SMC).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.